Phase 2 Trial of Obinutuzumab and CC-99282 for Patients With Previously Untreated High Tumor Burden Follicular Lymphoma

NCT06108232 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

33

Enrollment

OTHER

Sponsor class

Conditions

Follicular Lymphoma
Tumor

Interventions

DRUG: Obinutuzumab
DRUG: CC-99282

Sponsor

M.D. Anderson Cancer Center

Collaborators

[object Object]